Vemurafenib-associated neutrophilic panniculitis in a patient with metastatic amelanotic melanoma presenting as cancer of unknown primary origin

• Main Authors: Yu-Ching Weng (Author), Chien-Shan Chiu (Author), Tseng-Hsi Lin (Author), Jui-Lung Shen (Author), Chii-Shuenn Yang (Author), Joe-Bin Chen (Author)
• Format: Book
• Published: Wolters Kluwer Medknow Publications, 2016-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The treatment of metastatic melanoma is challenging. BRAF gene mutation is found in 40-60% of melanoma cases, the most common being the V600E mutation. Vemurafenib was approved by the Food and Drug Administration in 2011 as target therapy for the treatment with BRAF V600 mutation-positive metastatic...